You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
INSMED reported Brinsupri revenue of $400.1 million and Aircase revenue of $124.4 million for third-quarter 2026, raised full-year guidance and expects cash flow positivity in 2027. Aircase received FDA priority review with a January 28th, 2027 PDUFA target date.
Insmed reported third-quarter total revenue of $524.4 Million, including $400.1 Million from BRINSUPRI and $124.4 Million from ARIKAYCE. It raised full-year 2026 guidance to $1.35 Billion to $1.4 Billion for BRINSUPRI and $460 Million to $470 Million for ARIKAYCE.
INSMED Inc reported nine-month 2026 product revenues of $1,255.9 million, up 267% from $342.6 million, driven by BRINSUPRI’s $885.8 million U.S. sales growth. R&D rose 34% to $689.5 million and SG&A rose 53% to $747.8 million.
Insmed Incorporated appointed Paul Hudson and Utpal Koppikar as Board members effective October 19, 2026; Hudson joined the Compensation Committee, while Koppikar joined the Audit Committee.
Insmed Incorporated announced Sara Bonstein will step down as CFO effective October 30, 2026, and a successor search is underway. It reaffirmed full-year 2026 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE.
